Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women

Withdrawn before enrolling

Conditions studied: HIV Infected

In brief

Data suggests that women taking drugs to treat human immunodeficiency virus (HIV) have higher amounts of drugs in their body compared with men taking the same dose of anti-HIV drugs. The reason for this higher drug exposure has not yet been determined. The primary purpose of this study is to examine whether a pharmacokinetics (factors that determine the amount of drug in the body) of anti-HIV drugs change during different phases of the menstrual cycle in women and ultimately result in higher amounts of drug in the body compared with men. In other words, we plan to examine whether changes in sex hormones throughout the menstrual cycle affect the amount of anti-HIV drugs in HIV infected women. The antiretroviral drugs atazanavir, ritonavir, tenofovir and emtricitabine will be studied.

Key facts

Study ID
NCT01394133
Run by
University of Alabama at Birmingham
People needed
0
Starts
2011-07-01
Expected to finish
2013-04-01
Last updated by the study team
2013-04-30

Who can join

Age: 21 and older, up to 40. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.